Reven IP Holdco

Reven is a clinical-stage biopharmaceutical company focused on developing RJV-10, a proprietary intravenous formulation designed to treat complex metabolic and inflammatory conditions. The company's lead candidate, RJV-10, is being evaluated for its ability to manage oxidative stress and improve vascular health in patients with critical limb ischemia and peripheral arterial disease. Beyond cardiovascular indications, Reven is exploring the potential of its therapy in oncology and acute inflammatory responses such as sepsis and COVID-19-related respiratory distress. The company operates through various entities, including Reven IP Holdco, to manage its intellectual property and clinical development programs.